Amneal Pharmaceuticals, Metsera Strike Deal to Co-Develop Medicines for Obesity, Metabolic Diseases
Partnership is expected to leverage Amneal’s global manufacturing and product development experience and Metsera’s portfolio of ultra-long acting injectables and oral nutrient-stimulated hormone analogs.
Image Credit: Adobe Stock Images/Corona Borealis
Amneal Pharmaceuticals and Metsera announced that they have agreed to terms on a deal aimed at developing and supplying next-generation medicines for obesity and metabolic diseases. According to a joint statement, the collaboration will combine Amneal’s expertise in global manufacturing and product development with Metsera’s portfolio of ultra-long acting injectables and oral nutrient-stimulated hormone analogs. The deal comes amid promising results from Metsera’s Phase I trial for of its glucagon-like peptide-1 receptor agonist injectable, MET-097.1
“GLP-1s and other breakthrough obesity therapies have significant and wide-ranging health benefits for patients. Amneal is deeply committed to providing access to high-quality, affordable and essential medicines, including those in new categories. Through this strategic collaboration, we have the opportunity to extend our mission to a new portfolio of injectable and oral weight loss therapies. We are excited to work with Metsera and apply Amneal’s deep expertise in complex pharmaceutical manufacturing to bring these programs to market,” said Chirag and Chintu Patel, co-CEOs of Amneal, in a press release.
Under terms of the deal, Amneal will be Metsera’s preferred supply partner for developed markets such as the United States and Europe. Additionally, Amneal will receive commercialization rights in select emerging markets, including India and a number of countries in Southeast Asia, Africa, and the Middle East. In order to support this, Amneal plans on constructing two new manufacturing facilities in India, aiming to enhance peptide synthesis and sterile fill-finish capabilities.1
“With this collaboration, we have secured high-quality development and commercial scale capacity for our broad portfolio of ultra-long-acting injectable and oral NuSH analogs. Collaborating with Amneal brings dedicated access to unique capabilities and capacity not typically available to biotech firms at an early stage. These comprise access to Amneal’s drug substance manufacturing, product formulation and drug-device development capabilities, including its in-house API and sterile fill-finish, through both established and new state-of-the-art facilities,” said Whit Bernard, CEO, Metsera, in the press release.
Reference
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases. Amneal. October 1, 2024. Accessed October 1, 2024. https://investors.amneal.com/news/press-releases/press-release-details/2024/Amneal-and-Metsera-Announce-Strategic-Collaboration-to-Develop-and-Supply-Portfolio-of-Next-Generation-Medicines-for-Obesity-and-Metabolic-Diseases/default.aspx
GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease
May 14th 2025Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.
GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports
May 13th 2025Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.
